Mechanism underlying the transient increase of serum iron during FOLFOX/FOLFIRI therapy

Ochiai,Takumi; Nishimura,Kazuhiko; Watanabe,Tomoo; Kitajima,Masayuki; Nakatani,Akinori; Sato,Tsuyoshi; Kishine,Kenji; Futagawa,Shunji; Mashiko,Satomi; Nagaoka,Isao

doi:10.3892/mco.2014.385

November-December 2014 Volume 2 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-December 2014 Volume 2 Issue 6

Full Size Image

Article

Mechanism underlying the transient increase of serum iron during FOLFOX/FOLFIRI therapy

Authors:
- Takumi Ochiai
- Kazuhiko Nishimura
- Tomoo Watanabe
- Masayuki Kitajima
- Akinori Nakatani
- Tsuyoshi Sato
- Kenji Kishine
- Shunji Futagawa
- Satomi Mashiko
- Isao Nagaoka
View Affiliations / Copyright

Affiliations: Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan, Department of Pharmacy, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan, Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo 113-8421, Japan
Pages: 968-972
|
Published online on: August 11, 2014

https://doi.org/10.3892/mco.2014.385
Expand metrics +

Abstract

In patients with advanced colorectal cancer (CRC), a transient significant increase of serum iron is observed during chemotherapy with leucovorin and fluorouracil plus oxaliplatin (FOLFOX) or leucovorin and fluorouracil plus irinotecan (FOLFIRI). Serum iron may be a useful and convenient predictor of the response to chemotherapy; however, the mechanism underlying its increase has not been fully elucidated. Accordingly, the mechanism underlying the elevation of serum iron during chemotherapy was investigated in 20 patients with advanced CRC who were treated between September, 2012 and July, 2013. The levels of iron, ferritin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), hemoglobin (Hb), hepcidin-25, interleukin (IL)‑6 and soluble transferrin receptor (sTfR) were measured before and 48 h after chemotherapy. The serum levels of iron and hepcidin-25 were found to be significantly increased after chemotherapy (P<0.0001), whereas those of IL-6 were significantly decreased (P=0.0057). There were no significant changes in any of the other parameters. The lack of significant changes in AST, ALT and Hb suggested that the elevation of serum iron was not due to the destruction of hepatocytes, whereas the stable sTfR level suggested no destruction of erythroblasts. Hepcidin‑25 regulates iron metabolism and decreases serum iron levels; it is increased by an iron load and IL-6, but is decreased under anemic or hypoxic conditions. The suppression of erythropoiesis increases serum iron levels and chemotherapy suppresses erythropoiesis. As serum iron and hepcidin‑25 were both significantly increased and IL-6 was significantly decreased, with no significant changes in sTfR, it appears that the elevation of serum iron during chemotherapy may be secondary to reduced iron consumption by erythropoiesis, leading to increased expression of hepcidin‑25 and suppression of Il-6 via negative feedback.

View Figures

View References

1	Mashiko S, Nagaoka I, Kitajima M, et al: Evaluation of serum iron levels during FOLFOX4 and FOLFIRI therapies. Exp Ther Med. 1:507–511. 2010.PubMed/NCBI
2	Ochiai T, Nishimura K, Watanabe T, et al: Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs. Mol Clin Oncol. 1:805–810. 2013.PubMed/NCBI
3	Ochiai T, Nishimura K, Watanabe T, et al: Serum iron levels potential biomarker in FOLFOX/FOLFIRI with or without molecularly targeted drug therapy. J Clin Oncol. 31(Suppl): abs. e14651. 2013.
4	Watanabe T, Itabashi M, Shimada Y, et al: Cancer of the colon and rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 17:1–29. 2012. View Article : Google Scholar : PubMed/NCBI
5	Murphy AT, Witcher DR, Luan P and Wroblewski VJ: Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood. 110:1048–1054. 2007. View Article : Google Scholar : PubMed/NCBI
6	Murao N, Ishigai M, Yasuno H, Shimonaka Y and Aso Y: Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom. 21:4033–4038. 2007. View Article : Google Scholar
7	Kanda J, Mizumoto C, Kawabata H, et al: Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica. 93:1550–1554. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ponka P: Cellular iron metabolism. Kidney Int Suppl. 69:S2–S11. 1999. View Article : Google Scholar
9	Aisen P, Enns C and Wessling-Resnick M: Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 33:940–959. 2001. View Article : Google Scholar : PubMed/NCBI
10	Papanikolaou G and Pantopoulos K: Iron metabolism and toxicity. Toxicol Appl Pharmacol. 202:199–211. 2005. View Article : Google Scholar : PubMed/NCBI
11	Knutson M and Wessling-Resnick M: Iron metabolism in the reticuloendothelial system. Crit Rev Biochem Mol Biol. 38:61–88. 2003. View Article : Google Scholar
12	Krause A, Neitz S, Magert HJ, et al: LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480:147–150. 2000. View Article : Google Scholar : PubMed/NCBI
13	Park CH, Valore EV, Waring AJ, et al: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 276:7806–7810. 2001. View Article : Google Scholar : PubMed/NCBI
14	Kemna EH, Tjalsma H, Willems HL and Swinkels DW: Hepcidin: from discovery to differential diagnosis. Haematologica. 93:90–97. 2008. View Article : Google Scholar : PubMed/NCBI
15	Jordan JB, Poppe L, Haniu M, et al: Hepcidin revisited, disulfide connectivity, dynamics, and structure. J Biol Chem. 284:24155–24167. 2009. View Article : Google Scholar : PubMed/NCBI
16	Pigeon C, Ilyin G, Courselaud B, et al: A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 276:7811–7819. 2001. View Article : Google Scholar
17	Nicolas G, Chauvet C, Viatte L, et al: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 110:1037–1044. 2002. View Article : Google Scholar : PubMed/NCBI
18	Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A and Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 101:2461–2463. 2003. View Article : Google Scholar : PubMed/NCBI
19	Vokurka M, Krijt J, Sulc K and Necas E: Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 55:667–674. 2006.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Mechanism underlying the transient increase of serum iron during FOLFOX/FOLFIRI therapy

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles